http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01240.html
U.S. Food and Drug Administration
The U.S. Food and Drug Administration has approved an application for etanercept (trade-name Enbrel), a genetically engineered protein, for a new indication for treatment of patients with active ankylosing spondylitis (AS), a chronic inflammatory disease affecting primarily the lower back and joints.